(Q36909120)

17 August 2017

1 reference

title

Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs (English)

1 reference

17 August 2017

0 references

Benoit Drolet

1

1 reference

17 August 2017

Chantale Simard

series ordinal

2

1 reference

17 August 2017

Paul Poirier

series ordinal

3

1 reference

17 August 2017

publication date

1 January 2007

1 reference

American journal of cardiovascular drugs

17 August 2017

number of pages

16

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

273-288

1 reference

Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

The progression of fenfluramine-associated valvular heart disease assessed by echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Triggering myocardial infarction by marijuana

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Cardiovascular system effects of marijuana

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Lack of Cardiovascular Effects of Delta-9-Tetrahydrocannabinol in Chemically Denervated Men

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Regulation of fatty acid oxidation in the mammalian heart in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Human distribution and release of a putative new gut hormone, peptide YY

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

Stimulation of NPY Y2 receptors by PYY3-36 reveals divergent cardiovascular effects of endogenous NPY in rats on different dietary regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200707040-00005

10.2165/00129784-200707040-00005

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1004399237

0 references

1 reference